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EVALUATION OF METHOXSALEN IN THE TREATMENT OF VITILIGO
IRVING D. LONDON, M.D.
Montgomery, Atabamo
The value of the psoralen compounds in the
treatment of vitiligo has been documented in
this country since 1952 (1—6). Vitiligo is a dis-
ease of unknown etiology in which the pigment
rarely if ever has been known to return spon-
taneously to the involved areas (see p. 281).
At first, both 8-methoxypsoralen (methox-
salen) and 8-isoamylenoxypsoralen were used
together in capsules for oral administration and
mixed in a cream for topical use. Since 1955,
only methoxsalen has been used, after Kanof
(5) found that this compound was as effective
when used alone as when combined with 8-
isoamylenoxypsoralen. When methoxsalen, either
applied topically or taken orally, is followed by
exposure to gradually increasing doses of sun-
light or artificial ultraviolet light, gradual re-
pigmentation of vitiligo has been noticed in a
varying proportion of cases.
The author became interested in this treat-
ment for vitiligo in 1953 and has used these
compounds, along with controlled exposure to
sunlight or ultraviolet light in approximately
40 patients.
METHODS
In 1953 and 1954 the first group of patients was
treated with both oral and topical administration
of the mixed psoralens.* Approximately 15 pa-
tients received from two to six 10 mg. capsules of
the mixed psoralens daily, divided into two or
three doses. The one per cent cream was also
applied once daily to the lesions. The patients
were instructed to expose themselves to increasing
amounts of sunlight or ultraviolet light at least
five times weekly.
Since 1955 most of the patients were treated by
the oral administration of methoxsalen, 20 mg.
daily being taken two hours prior to carefully
measured exposures to the mid-day sun or ultra-
Presented at the Brook Lodge Invitational
Symposium on the Psoralens, sponsored by the
Upjohn Company, Kalamazoo, Michigan, March
27—28, 1958.
* The mixed oral psoralens contained 10 mg.,
S-methoxypsnralen and 5 mg. 8-isoamylenoxy-
psoralen. Bi-psoralen cream contained 0.75%
S-methoxypsoralen and 0.25% 8-isoamylenoxy-
psoralen.
violet light from a General Electric R.S. Sunlamp
bulb. The amount of exposure was gradually in-
creased, based on the patient's tolerance. Another
group was treated by topical application of one
per cent methoxsalen paint over small patches of
vitiligo followed by exposure to sunlight or sun-
lamp.
No statistical analysis will be attempted in this
paper for several reasons. First, several patients
were lost from view after several months of treat-
ment. Some were seen at distant clinics and these
records were not available during the preparation
of this paper. A few patients had to stop taking
the drug because of toxic reactions. Lastly, the
technics of administration of the psoralens were
not always comparable. I shall, therefore, discuss
not statistics but the results in general of the
various technies especially as they pertain to
individual patients.
TOPICAL THERAPY
The intensity of sunlight in the deep South
must be reckoned with in the topical application
of methoxsalen to vitiligo. In practically all
cases in which mcthoxsalcn lotion was applied
to an exposed surface, such as hands, neck or
face, burning and vesiculation followed the
exposure to sunlight, after one or several treat-
ments. This was probably due not only to the
intensity of the measured therapeutic exposure
but also to additional casual exposures the pa-
tient unsuspectingly received while out in the
sun following treatment. The worst such case
occurred in September, 1956. This was a white
male, age 36, who had only one application of
methoxsalen to the white spots on his hands.
Five to ten minutes later he exposed his hands
for only one minute to noonday sun. Severe,
intensive burning with the formation of large
blisters on these areas resulted overnight. These
blisters persisted for fourteen days and the
patient required oral steroid therapy to clear
them. The patient admitted that he was out
of doors with his hands exposed to the sun the
afternoon following the mcthoxsalen lotion.
Contact dermatitis, with or without blistering,
has also been noticed in the colored patients
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who have used the topical application. One
colored child, however, did have burning and
blistering of several spots on his face treated
last year and now reports that without any
further treatment the lesions have repigmented
and have remained so up to the present. Topical
methoxsalen therapy was used successfully in
two other colored patients whose lesions were
under the clothing; one on the thighs, another
on the chest. These patients did not have any
burn or vesiculation with their treatment. This
observation, therefore, leads to the conclusion
that severe reactions are due to additional
casual exposures to sunlight in uncovered areas
treated with topical methoxsalen. In general,
topical psoralen therapy should be used with
extreme caution in the Southern states on the
exposed surfaces of the body and with cautiously
controlled sunlight or sunlamp therapy where
the lesions are on the areas covered by clothing.
RESPONSE TO ORAL THERAPY
About 35 patients were treated orally with
methoxsalen. Most of these patients showed
some beginning repigmentation in two weeks
to two months after the onset of treatment.
Those that showed no repigmentation in two
months failed to show any afterwards. The
dorsa of the hands most often failed to show
repigmentation. The repigmentation was usually
in the form of perifollicular ephelis-like lesions
or a filling-in of pigment from the periphery.
With continuation of therapy, these macules
became coalesced to form large patches of pig-
ment which would eventually fill in the defect.
As has been previously observed (8, 9), the
normal skin exposed to the sun or ultraviolet
light after methoxsalen tans excessively or be-
comes hyperpigmented. In vitiligo the white
spots become surrounded by hyperpigmented
areas making them become more prominent and
bizarre in appearance, thereby causing many
white women to stop the treatment. Another
commonly noted finding with oral medication is
the fact that this therapy has had to be continued
indefinitely because leaving the drug off or re-
ducing the dose produced a relapse of the vitiligo.
Colored patients responded much better to
the oral administration of the psoralens than
did the white patients. Children responded
faster and again more completely than adults.
In this series were several colored children, ages
five to 11 and one white child, age 11. One colored
child, age nine, became completely repigmented
and has continued to receive one or two capsules
daily for over one and one-half years without
any harmful effect. Her pigmentation persists.
A white male, age 43, has been on methoxsalen
for three years with only several short breaks in
the treatment. These breaks were necessitated
by a hernia operation two years ago and again
by a short bout of influenza this past winter.
This patient has had vitiligo for fifteen years.
His lesions were scattered over the face, neck,
hands and body. He was mainly interested in
obtaining a decent cosmetic appearance of the
leukodermic spots on his face and neck. The
vitiligo on these areas showed some repigmenta-
tion with typical perifollicular distribution of
the melanin pigment within several weeks, and
complete repigmentation within four to five
months. Since then there was some regression
of the vitiligo when he was unable to take the
drug or when he diminished it to one capsule
daily. With higher doses he becomes very nervous,
upset and depressed.
TOXIC REACTIONS
In the early group, which consisted of about
fifteen patients, liver function studies were per-
formed. One of these patients had a 2-plus
eephalin flocculation test about two months
after commencing therapy, but had not had a
prior test. This was not considered significant.
Liver function studies have not been performed
in this investigation since 1954.
Toxic reactions of mild to moderate degree
were noted with oral methoxsalen therapy from
the beginning of this study. Two patients dis-
continued oral treatment because of severe nausea
and vomiting. In 1954, a white female, age 17, had
persistent nausea and vomiting, lasting four or
five days, after taking one capsule. A second pa-
tient noticed very little repigmentation after two
months of therapy and because of the severe
nausea and vomiting on one capsule daily dis-
continued treatment. SeYeral patients discon-
tinued methoxsalen because of severe nervous-
ness. Three patients noticed erythema and itching
following oral methoxsalen therapy.
In response to a recent questionnaire, the
following reasons were noted for discontinuing
therapy:
1. Toxic symptoms: severe nausea and vomit-
ing, nervousness, blistering and dermatitis.
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2. The treatment was too prolonged and in
most instances had to be continued indefinitely.
3. Many patients, especially women, objected
to the hyperpigmentation surrounding the
vitiliginous areas which made these areas more
prominent during the early stages of therapy
and during the summers.
DIscussIoN
In 1955, in discussing Elliott's paper (7) at
the Southern Medical Association meeting in
Houston, the writer raised the question of the
recurrence of vitiligo in the healed areas and the
necessity of continuing treatment indefinitely
with oral mcthoxsalcn therapy. It is now com-
monly noted that dcpigmcntation follows dis-
continuation or decreasing the oral dosage of
the methoxsalcn.
In reviewing two recent papers on topical or
combined therapy, it is noted that George and
Burks (4), and Sheldon et at. (6) speak of "cures."
Complete rcpigmcntation took place in George's
group in two of eleven patients in from two weeks
to two months and in Sheldon's group in four
of twenty-five patients in about four months.
All these patients received topical therapy; some
also took oral mcthoxsalen. Neither paper men-
tions dcpigmcntation occurring when therapy
stopped. In the present survey, three patients
had complete rcpigmcntation which has per-
sisted for six months to one year following topical
treatment. It is therefore probable that topical
therapy is more efficacious and longer-lasting
than oral methoxsalcn, despite the fact that
dermatitis may result from the topical applica-
tions.
5UMMARY AND cONcLUsIONs
Topical therapy of vitiligo with mcthoxsalen
should be used with great caution on the exposed
surfaces of patients residing in the Southern
states. This treatment may be applied with less
danger on the covered areas of the body. Topical
therapy results in longer lasting repigmentation
of vitiligo.
Repigmcntation on oral therapy will commence
within two months, if at all. Medication must be
continued indefinitely to maintain repigmenta-
tion.
Colored children have uniformly shown a
good response, with a more rapid onset of benefit
and more complete end result.
Oral mcthoxsalcn therapy is recommended
for patients who arc practical and patient, and
who will be satisfied with a reasonable cosmetic
rcpigmcntation of the face and neck. The pa-
tient with generalized vitiligo who wants to
rcpigmcnt all the affected areas should be dis-
couraged from beginning or attempting treat-
ment.
The toxic effects of mcthoxsalcn include severe
nausea and vomiting, severe nervousness, de-
pression, and dermatitis with blistering.
The reasons given by patients for discontinu-
ing therapy were: (a) severe toxic symptoms,
(b) slowness of rcpigmcntation, (c) the prolonged
treatment that is necessary, and (d) the bizarre
accentuation of the vitiligo because of surround-
ing hypcrpigmcntation.
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